Researchers at Tulane University have identified a potential new way to treat idiopathic pulmonary fibrosis (IPF), a deadly and currently incurable lung disease that affects more than 3 million people ...

In August 2025, the FDA gave accelerated approval to Hernexeos for patients with previously treated metastatic or unresectable non-squamous NSCLC who had HER2 TKD activating mutations, as detected by ...

When breathing becomes increasingly difficult with no clear explanation, idiopathic pulmonary fibrosis (IPF) might be the culprit behind the concerning symptoms. This rare yet devastating lung disease ...

The investigators also reported that LTI-03 helped preserve alveolar epithelial type II (AT2) progenitor cells, which are essential for lung repair and regeneration. Current IPF therapies primarily ...

Idiopathic pulmonary fibrosis stands as one of medicine’s most challenging respiratory conditions, gradually transforming healthy lung tissue into stiff, scarred material that severely compromises ...

The long-term effects of respiratory viral infections such as COVID-19 are a major public health burden. Some estimates suggest over 65 million people around the world suffer from long COVID-19.

For patients affected by lung diseases such as pulmonary fibrosis, chronic obstructive pulmonary disease, cystic fibrosis and others, cures for their diseases are incredibly rare, if not nonexistent. ...

Pulmonary sarcoidosis is a condition that causes tiny groups of immune cells to clump in your lungs. These groups of cells form swollen, inflamed lumps called granulomas. Granulomas can make it hard ...